Search

Fesoterodine

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Tenapanor

In October 2023, tenapanor was approved for the treatment of chronic kidney disease.[L48511] … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).

DFV890

DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

Juniper tar

Rucaparib

an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with

HSD-016

Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).

Halcinonide

Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. … Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc.

Gepirone

[A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.

Pemoline

In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

Patupilone

Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.